Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Cold War tensions and the polio vaccine flew to Leningrad in June, 1956. As a result of a cooperation of Sabin and Chumakov in Leningrad, Sabin was able to test his attenuated vaccine when funding in America was declined. While Sabin was working behind the Iron Curtain, the Sabin-Chumakov vaccine was determined to be safe and effective. Cold War tensions caused Western scientists to refuse the reports from the Russians about the effectiveness of the Sabin vaccine. However, mass vaccinations of Sabin's vaccine spread throughout Eastern Europe from 1960–1963. Just as some Soviet virologists did not trust the Western Salk vaccine, Americans had similar reservations about the